Companies Dominating the Hepatitis B Treatment Landscape
- GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol-Myers Squibb Company
- Sanofi-aventis Groupe
- F. Hoffmann-La Roche Ltd.
- India Immunologicals Ltd.
- Merck & Co., Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of hepatitis B treatment is evaluated at USD 96.07 billion.
Hepatitis B Treatment Market size was valued at USD 92.61 billion in 2024 and is expected to reach USD 162.09 billion by 2037, expanding at around 4.4% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is expected to account for largest revenue share by 2037, owing to increasing prevalence of the viral disease in nations, such as China, Mongolia, Korea, Vietnam, and others.
The major players in the market are GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi-aventis Groupe, F. Hoffmann-La Roche Ltd., India Immunologicals Ltd., Merck & Co., Inc., Novartis AG, and others.
